cytarabine and daunorubicin

cytarabine and idarubicin

daunorubicin and cytarabine, liposome *for pts who are suitable for intensive therapy and age ≥60 years; therapy related AML or AML from prior MDS*

azacitidine or decitabine and venetoclax *for patients that are not suitable for intensive therapy, e.g. unfit elderly patients*

cytarabine, daunorubicin and midostaurin *FLT3 mutation*

cytarabine, idarubicin and midostaurin *FLT3 mutation*

ivosidenib and azacitidine *IDH1 mutation positive*

quizartinib and cytarabine and daunorubicin or idarubicin *FLT3-ITD mutation*

cytarabine and daunorubicin

cytarabine and idarubicin

daunorubicin and cytarabine, liposome *for pts who are suitable for intensive therapy and age ≥60 years; therapy related AML or AML from prior MDS*

HiDAC (high dose cytarabine)

cytarabine and midostaurin *FLT3 mutation*

quizartinib and cytarabine *FLT3-ITD mutation*

quizartinib *FLT3-ITD mutation* who previously received quizartinib and with no allogeneic HCT planned

cytarabine and daunorubicin

cytarabine and idarubicin

fludarabine and cytarabine

fludarabine, cytarabine and idarubicin (FLAG-IDA)

ivosidenib *IDH-1 mutation positive*

enasidenib *IDH-2 mutation positive*

gilteritinib *FLT3 mutation positive*

Best Supportive Care or Clinical Trial